BMSSC
IOVA icon

B. Metzler seel. Sohn & Co’s Iovance Biotherapeutics IOVA Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,085
Closed -$318K – 745
2022
Q1 		$318K Buy
+19,085
New +$295K ﹤0.01% 680

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

B. Metzler seel. Sohn & Co's IOVA Position: Q2 2022 in Review

B. Metzler seel. Sohn & Co sold out of Iovance Biotherapeutics (IOVA) in Q2 2022, closing a stake of 19,085 shares — an estimated $318K sold.

B. Metzler seel. Sohn & Co first reported a position in IOVA in Q1 2022 and held it in 1 quarter. The position peaked at $318K in Q1 2022. 237 funds tracked by Wall St. Rank hold IOVA as of Q2 2022.

  • B. Metzler seel. Sohn & Co reported no remaining Iovance Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 19,085 Iovance Biotherapeutics shares in Q2 2022, an estimated $318K.
  • B. Metzler seel. Sohn & Co first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 1 quarter.
  • B. Metzler seel. Sohn & Co's Iovance Biotherapeutics position peaked at $318K in Q1 2022.
  • 237 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2022.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2022, filed 12 Aug 2022.